

SAN FRANCISCO, February 3, 2015 (GLOBE NEWSWIRE) -- ProLynx LLC, a biotechnology company focused on development of a novel platform for half-life extension of injectable drugs – peptides, proteins and small molecules – today announced that the United States Patent and Trademark Office has issued US Patent 8,946,405 entitled “Controlled Release from Solid Supports”. The patent broadly covers the controlled release of drugs or pro-drugs using ProLynx’s beta-eliminative linkers on insoluble supports.

The recently issued patent is part of a growing intellectual property portfolio that now includes four issued US patents and eight pending US applications, along with corresponding international applications.

"This patent is an important component of ProLynx's intellectual property portfolio since it extends the utility of our beta-eliminative linkers to long-acting drugs that are attached to our hydrogels and other insoluble carriers." said Founder and President Daniel V. Santi, M.D., Ph.D. "In addition to long-duration systemic therapy through subcutaneous injections, the technology expands potential utility to intra-articular, intra-vitreous injections, and other localized therapies". Gary Ashley, Chief Scientific Officer, stated “We can now control drug release from conjugates made with almost any carrier. Moreover, the technology uniquely enables half-life extensions of certain drugs to one month or, in localized compartments, even longer”.

#### About ProLynx LLC

ProLynx LLC is a privately held biotechnology company developing proprietary drug delivery systems (DDS) for half-life extension of proteins, peptides and small molecules. The company is seeking to apply its DDS to extend half-lives of drugs and drug candidates of pharmaceutical and biotechnology companies. ProLynx is also seeking to out-license the long lasting drug conjugates in its pre-clinical product portfolio. The company is located in San Francisco, CA. Further information about the company and its capabilities may be found online at <http://www.prolynxllc.com>.

Contact: Eric Schneider: [Eric@Prolynxllc.com](mailto:Eric@Prolynxllc.com)